The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Aksenov V.A.

Vice-president of the Inter-Regional Association of Evidence-Based Medicine, Orenburg, Russia

Nikonov E.L.

FGBU "Poliklinika #1" Upravleniia delami Prezidenta RF

The application of probiotics for the treatment of inflammatory bowel diseases, hepatopathy, and infectious diseases

Authors:

Aksenov V.A., Nikonov E.L.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2017;6(2): 35‑45

DOI: 10.17116/dokgastro20176235-45

Read: 39806 times

Download PDF (RU)
Contact the author
Table of contents

THE APPLICATION OF PROBIOTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES, HEPATOPATHY, AND INFECTIOUS DISEASES
THE APPLICATION OF PROBIOTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES, HEPATOPATHY, AND INFECTIOUS DISEASES

To cite this article:

Aksenov VA, Nikonov EL. The application of probiotics for the treatment of inflammatory bowel diseases, hepatopathy, and infectious diseases. Russian Journal of Evidence-Based Gastroenterology. 2017;6(2):35‑45. (In Russ.)
https://doi.org/10.17116/dokgastro20176235-45

Подписка 2026 Доказательная гастроэнтерология (Russian Journal of Evidence-Based Gastroenterology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Celiac disease in men aged 18—27: new data on prevalence and clinical features. Russian Journal of Evidence-Based Gastroenterology. 2025;(1):55-62
Differential diagnosis of anemia in ulce­rative coli­tis: a clinical case. Russian Journal of Evidence-Based Gastroenterology. 2025;(2):115-120
High-throughput sequencing: a powe­rful tool for pathogen dete­ction and identification in clinical samples. Labo­ratory Service. 2024;(4):49-56
Influence of enzy­matic acti­vity of microbiota on hemo­dynamics, arte­rial stiffness and emotional state of patients with mild-to-moderate risk of cardiovascular complications. Russian Cardiology Bulletin. 2024;(4-2):128-136
Nutrition, inte­stinal microbiota, and thyroid autoimmune pathology. Russian Journal of Preventive Medi­cine. 2025;(1):102-108
Nutrition correction in the complex therapy and reha­bilitation of the posttraumatic stress diso­rder. Russian Journal of Preventive Medi­cine. 2025;(2):114-119
Asso­ciations between the gut microbiota-derived meta­bolites with the para­meters of 24-hour ambu­latory blood pressure moni­toring in patients on maintenance hemo­dialysis. Russian Journal of Preventive Medi­cine. 2025;(3):96-102
Clinical case of disturbance of the gut microbiota due to the use of braces-system. Russian Journal of Stomatology. 2025;(1):36-39
Impact of alco­hol consumption on nature of nutrition, meta­bolism and human target organs. Part 3. The role and significance of micronutrients. Russian Journal of Preventive Medi­cine. 2025;(5):117-123
Moni­toring of the postoperative period of dental implant placement to assess the microbiota of the periimplant sulcus. Russian Journal of Stomatology. 2025;(2):45-51
Abstract:

Changes in the intestinal microbiota and imbalance of the intestinal microflora (dysbiosis) can be responsible for the negative consequences for the digestive process such as the impairment of the hepatic detoxification function and the development of various disorders including the inflammatory bowel disease and hepatopathies. This review article presents the data concerning the effectiveness of the application of probiotics for the treatment of inflammatory bowel diseases (IBD), hepatopathy, and various infectious diseases.

Keywords:

intestinal microbiota
probiotics
inflammatory bowel diseases
hepatopathy
virulent diseases
intestinal microbiota
probiotics
inflammatory bowel diseases
hepatopathy
virulent diseases

Authors:

Aksenov V.A.

Vice-president of the Inter-Regional Association of Evidence-Based Medicine, Orenburg, Russia

Nikonov E.L.

FGBU "Poliklinika #1" Upravleniia delami Prezidenta RF

Close metadata

References:

  1. Penner R, Fedorak RN, Madsen KL. Probiotics and nutraceu-ticals: non-medicinal treatments of gastrointestinal diseases. Curr Opin Pharmacol. 2005;5:596-603. https://doi.org/10.1016/j.coph.2005.06.009
  2. Sullivan A, Nord CE. Probiotics and gastrointestinal diseases. J Intern Med. 2005;257:78-92. https://doi.org/10.1111/j.1365-2796.2004.01410.x
  3. Passariello A, Agricole P, Malfertheiner P. A critical appraisal of probiotics (as drugs or food supplements) in gastrointestinal diseases. Curr Med Res Opin. 2014;30(6):1055-1064. https://doi.org/10.1185/03007995.2014.898138
  4. Celiberto LS, Bedani R, Rossi EA, Cavallini DC. Probiotics: The scientific evidence in the context of inflammatory bowel disease. Crit Rev Food Sci Nutr. 2017;57(9):1759-1768. https://doi.org/10.1080/10408398.2014.941457
  5. Anand G, Zarrinpar A, Loomba R. Targeting Dysbiosis for the Treatment of Liver Disease. Semin Liver Dis. 2016;36(1):37-47. https://doi.org/10.1055/s-0035-1571276
  6. Food and Agricultural Organization of the United Nations and World Health Organization. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Cordoba, Argentina, 1—4 October 2001. Available at: http://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwj919j2zLjVAhUBNxQKHYGmDjsQFggnMAA&url=http%3A%2F%2Fwww.fao.org%2F3%2Fa-a0512e.pdf&usg=AFQjCNFM5mIikTPKEsZNDl7y548Tjr4khw
  7. Osadchuk M, Balashov D, Osadchuk M. The use of probiotics in the practice of a therapist. Terapiya. 2016;2(6):35-42. (In Russ.).
  8. Sebastián Domingo JJ. Review of the role of probiotics in gastrointestinal diseases in adults. Gastroenterol Hepatol. 2017;40(6):417-429. https://doi.org/10.1016/j.gastre.2016.12.001
  9. Gerardi V, Bruno G, Petito V, Scaldaferr F. Inflammatory Bowel Diseases In: The Gut Microbiota The 4th organ of the Digestive System. Roma; 2013:18-21.
  10. Comito D, Cascio A, Romano C. Microbiota biodiversity in inflammatory bowel disease. Italian Journal of Pediatrics. 2014;40(1):32-40. https://doi.org/10.1186/1824-7288-40-32
  11. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066-2078. https://doi.org/10.1056/nejmra0804647
  12. Sartor RB. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology. 2010;139:1816-1819. https://doi.org/10.1053/j.gastro.2010.10.036
  13. Veerappan GR, Betteridge J, Young PE. Probiotics for the treatment of inflammatory bowel disease. Curr Gastroenterol Reports. 2012;14(4):324-333. https://doi.org/10.1007/s11894-012-0265-5
  14. Osipenko M, Skalinskaya M, Razmerica A. Probiotics and inflammatory bowel diseases. Gastroenterologiya. (suppl. Consilium Medicum). 2013;2:28-31. (In Russ.).
  15. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118(2):229-241. https://doi.org/10.1016/j.cell.2004.07.002
  16. Dong J, Teng G, Wei T, Gao W, Wang H. Methodological quality assessment of meta-analyses and systematic reviews of probiotics in inflammatory bowel disease and pouchitis. PLoS ONE. 2016;11:e0168785. https://doi.org/10.1371/journal.pone.0168785
  17. Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2014;20:21-35.
  18. Fujiya M, Ueno N, Kohgo Y. Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials. Clin J Gastroenterol. 2014;7:1-13. https://doi.org/10.1007/s12328-013-0440-8
  19. Ganji-Arjenaki M, Rafieian-Kopaei M. Probiotics are a good choice in remission of inflammatory bowel diseases: a meta analysis and systematic review. J Cell Physiol. 2017. https://doi.org/10.1002/jcp.25911
  20. Sang LX, Chang B, Zhang WL, Wu XM, Li XH, Jiang M. Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J Gastroenterol. 2010;16:1908-1915. https://doi.org/10.3748/wjg.v16.i15.1908
  21. Rahimi R, Nikfar S, Rahimi F. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn’s disease. Dig Dis Sci. 2008;53:2524-2531. https://doi.org/10.1007/s10620-007-0171-0
  22. Shen J, Ran HZ, Yin MH, Zhou TX, Xiao DS. Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease. Intern Med J. 2009;39:103-109. https://doi.org/10.1111/j.1445-5994.2008.01791.x
  23. Derwa Y, Gracie DJ, Hamlin PJ, Ford AC. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Jun 27. https://doi.org/10.1111/apt.14203
  24. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635-639. https://doi.org/10.1016/s0140-6736(98)06343-0
  25. Kato K, Mizuno S, Umesaki Y. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004;20:1133-1141. https://doi.org/10.1111/j.1365-2036.2004.02268.x
  26. Sood A, Midha V, Makharia GK. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1202-1209e1. https://doi.org/10.1016/j.cgh.2009.07.016
  27. Petersen AM, Mirsepasi H, Halkjaer SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J Crohns Colitis. 2014;8:1498-1505. https://doi.org/10.1016/j.crohns.2014.06.001
  28. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med. 2010;10:13. https://doi.org/10.1186/1472-6882-10-13
  29. Ng SC, Plamondon S, Kamm MA. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis. 2010;16:1286-1298. https://doi.org/10.1002/ibd.21222
  30. Tursi A, Brandimarte G, Papa A. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105:2218-2227. https://doi.org/10.1038/ajg.2010.218
  31. Tamaki H, Nakase H, Inoue S. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: a randomized, double-blinded, placebo-controlled multicenter trial. Dig Endosc. 2015;28:67-74. https://doi.org/10.1111/den.12553
  32. Zocco MA, dal Verme LZ, Cremonini F. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23(11):1567-1574. https://doi.org/10.1111/j.1365-2036.2006.02927.x
  33. Kruis W, Fric P, Pokrotnieks J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617-1623. https://doi.org/10.1136/gut.2003.037747
  34. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997;11:853-858. https://doi.org/10.1136/gut.2003.037747
  35. Cui HH, Chen CL, Wang JD. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol. 2004;10(10):1521-1525. https://doi.org/10.3748/wjg.v10.i10.1521
  36. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomized double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis. 2011;5(2):115-121. https://doi.org/10.1016/j.crohns.2010.11.004
  37. Yoshimatsu Y, Yamada A, Furukawa R. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World J Gastroenterol. 2015;21:5985-5994. https://doi.org/10.3748/wjg.v21.i19.5985
  38. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol. 2004;4(1):4:5. https://doi.org/10.1186/1471-230x-4-5
  39. Malchow HA. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease. J Clin Gastroenterol. 1997;25(4):653-658. https://doi.org/10.1097/00004836-199712000-00021
  40. Bourreille A, Cadiot G, Le Dreau G. Saccharomyces boulardii does not prevent relapse of Crohn’s disease. Clin Gastroenterol Hepatol. 2013;11(8):982-987. https://doi.org/10.1016/j.cgh.2013.02.021
  41. Willert RP, Peddi KK, Ombiga J, Bampton PA, Lawrance IC. T1235 randomized, double-blinded, placebo-controlled study of VSL#3 versus placebo in the maintenance of remission in crohns disease. Gastroenterology. 2010;138(5):S-517. https://doi.org/10.1016/s0016-5085(10)62390-6
  42. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956-963. https://doi.org/10.1016/0016-5085(90)90613-6
  43. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomized controlled trial with Lactobacillus GG. Gut. 2002;51(3):405-409. https://doi.org/10.1136/gut.51.3.405
  44. Van Gossum A, Dewit O, Louis E. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after lleo-caecal resection. Inflamm Bowel Dis. 2007;13(2):135-142. https://doi.org/10.1002/ibd.20063
  45. Marteau P, Lemann M, Seksik P. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomized, double blind, placebo controlled GETAID trial. Gut. 2006;55(6):842-847. https://doi.org/10.1136/gut.2005.076604
  46. Fedorak RN, Feagan BG, Hotte N. The probiotic VSL#3 has antiinflammatory effects and could reduce endoscopic recurrence after surgery for Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(5):928-935. https://doi.org/10.1016/j.cgh.2014.10.031
  47. Wigg AJ, Robert-Thompson JG, Dymock RB. The role small Intestinal bacterial overgrowth, intestinal permeability, endotoxaemla and tumor necrosis factor-alfa in a pathogenesis of nonalcoholic steatohepatitis. Gut. 2001;48(2):206-211. https://doi.org/10.1136/gut.48.2.206
  48. Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database of Systematic Reviews 2017, Issue 2. Art. No.: CD008716. https://doi.org/10.1002/14651858.cd008716.pub3
  49. EASL—EASD—EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1988-1402. https://doi.org/10.1016/j.jhep.2015.11.004
  50. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1):S47-S64. https://doi.org/10.1016/j.jhep.2014.12.012
  51. Leuschner U. Non-alcoholic steatohepatitis (NASH). 2008, 2009, 7th ed.
  52. Wieland A, Frank DN, Harnke B, Bambha K. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2015;42(9):1051-1063. https://doi.org/10.1111/apt.13376
  53. Abu-Shanab A, Quigley EM. The role of the gut microbiota in non-alcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7(12):691-701. https://doi.org/10.1038/nrgastro.2010.172
  54. Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev. 2007;(1):CD005165. https://doi.org/10.1002/14651858.cd005165.pub2
  55. Aller R, De Luis DA, Izaola, O, Conde R., Gonzalez Sagrado M, Primo D, de la Fuente B, Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15:1090-1095.
  56. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol. 2011;45(8):679-683. https://doi.org/10.1097/mcg.0b013e318204593e
  57. Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, Reali L, Anania F, Nobili V. Randomised clinical trial: The beneficial effects of VLS_3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39(11):1276-1285. https://doi.org/10.1111/apt.12758
  58. Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, Caropreso M, Vallone G, Meli R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Gastroenterol Nutr. 2011;52(6):740-743. https://doi.org/10.1097/mpg.0b013e31821f9b85
  59. Sepideh A, Karim P, Hossein A. Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial. J Am Coll Nutr. 2015;35(6):500-505. https://doi.org/10.1080/07315724.2015.1031355
  60. Guarino A, Ashkenazi S, Gendrel D. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/ European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: Update 2014. Zhonghua Er Ke Za Zhi. 2015;53:499-509.
  61. Gottlieb T, Heather CS. Diarrhoea in adults (acute). BMJ Clin Evid. 2011. PMID: 21718555. PMCID:PMC3217748
  62. Guarino A, Dupont C, Gorelov AV. The management of acute diarrhea in children in developed and developing areas: From evidence base to clinical practice. Expert Opin Pharma-cother. 2011;13(1):17-26. https://doi.org/10.1517/14656566.2011.634800
  63. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhea. Cochrane Database Syst Rev. 2010;11:96. https://doi.org/10.1002/14651858.cd003048.pub3
  64. Van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics. 2002;109(4):678-684. https://doi.org/10.1542/peds.109.4.678
  65. Applegate JA, Fischer Walker CL, Ambikapathi R. Systematic review of probiotics for the treatment ofcommunity-acquired acute diarrhea in children. BMC PublicHealth. 2013;13(Suppl.3):S16-S39.
  66. Szajewska H, Guarino A, Hojsak I. Use of probiotics formanagement of acute gastroenteritis: A position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 2014;58(4):531-539. https://doi.org/10.1097/mpg.0000000000000320
  67. Sazawal S, Hiremath G, Dhingra U. Efficacy of probiotics in prevention of acute diarrhoea: A meta-analysis of masked, randomized, placebo-controlled trials. Lancet Infect Dis. 2006;6(6):374-382. https://doi.org/10.1016/s1473-3099(06)70495-9
  68. McFarland LV. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis. 2007;5(2):97-105.
  69. Gerding DN, Lessa FC. The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect Dis Clin North Am. 2015;29(1):37-50. https://doi.org/10.1016/j.idc.2014.11.004
  70. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008. https://doi.org/10.1002/14651858.cd004611.pub2
  71. Johnson S, Maziade PJ, McFarland LV. Is primary prevention of Clostridium difficile infection possible with specific probiotics. Int J Infect Dis. 2012;16(11):e786-e792. https://doi.org/10.1016/j.ijid.2012.06.005
  72. Szajewska H, Ruszczynski M, Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: A meta-analysis of randomized controlled trials. J Pediatr. 2006;149(3):367-372. https://doi.org/10.1016/j.jpeds.2006.04.053
  73. O’Horo JC, Jindai K, Kunzer B. Treatment of recurrent Clostridium difficile infection: A systematic review. Infection.2013;42(1):43-59. https://doi.org/10.1007/s15010-013-0496-x
  74. Evans CT, Johnson S. Prevention of Clostridium difficile infection with probiotics. Clin Infect Dis. 2015;60(Suppl.2):S122-S128. https://doi.org/10.1093/cid/civ138
  75. Johnston BC, Ma SS, Goldenberg JZ. Probiotics for the prevention of Clostridium difficile-associated diarrhea: A systematic review and meta-analysis. Ann Intern Med. 2012;157(12):878-888. https://doi.org/10.7326/0003-4819-157-12-201212180-00563
  76. Goldenberg JZ, Ma SS, Saxton JD. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013. https://doi.org/10.1002/14651858.cd006095.pub3
  77. Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PloS One. 2014;9(11):e111030. https://doi.org/10.1371/journal.pone.0111030
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.